Patients’ characteristics according to the conditioning regimen for HSCT
| . | Total . | MAC . | RIC/NMA . |
|---|---|---|---|
| N | 43 | 14 | 29 |
| Age, y | 57 (20-72) | 36 (20-50) | 61 (32-72) |
| Sex (M/F) | 29/14 | 8/6 | 21/8 |
| F → M | 11 (26%) | 3 (21%) | 8 (28%) |
| Other | 32 (74%) | 11 (79%) | 21 (72%) |
| Time from diagnosis, d | 170 (107-1050) | 147.5 (110-520) | 193 (107-1050) |
| Disease status at HSCT | |||
| CR1 | 34 (79%) | 12 (86%) | 23 (79%) |
| CR2 | 5 (12%) | 1 (7%) | 4 (14%) |
| No CR | 2 (5%) | 1 (7%) | 0 |
| Unknown | 2 (5%) | 0 | 2 (7%) |
| Donor | |||
| Sibling | 19 (44%) | 8 (57%) | 11 (38%) |
| MUD | 10 (23%) | 1 (7%) | 9 (31%) |
| MMUD | 7 (16%) | 4 (29%) | 3 (10%) |
| Cord blood | 6 (14%) | 1 (7%) | 5 (17%) |
| Mismatch relative | 1 (2%) | 0 | 1 (3%) |
| Conditioning regimen | |||
| MAC | 14 (33%) | 14 (100%) | NA |
| Cy/TBI-based | 11 (26%) | 11 (79%) | NA |
| Cy/Bu | 3 (7%) | 3 (21%) | NA |
| RIC/NMA | 29 (67%) | NA | 29 (100%) |
| Flu/Bu/ALG | 10 (23%) | NA | 10 (34%) |
| Flu/2 Gy-TBI | 10 (23%) | NA | 10 (34%) |
| Sequential* | 5 (12%) | NA | 5 (17%) |
| Other† | 4 (9%) | NA | 4 (14%) |
| TBI-based | 23 (53%) | 11 (79%) | 12 (41%) |
| Cell source | |||
| Bone marrow | 7 (16%) | 5 (36%) | 2 (7%) |
| Peripheral blood | 30 (70%) | 8 (57%) | 22 (76%) |
| Cord blood | 6 (14%) | 1 (7%) | 5 (17%) |
| CMV status (D/R) | |||
| −/− | 18 (42%) | 6 (43%) | 12 (41%) |
| −/+ | 9 (21%) | 1 (7%) | 8 (28%) |
| +/− | 4 (9%) | 2 (14%) | 2 (7%) |
| +/+ | 12 (28%) | 5 (36%) | 7 (24%) |
| GVHD prophylaxis | |||
| Ciclo/MTX | 15 (35%) | 12 (86%) | 3 (10%) |
| Ciclo/MMF | 19 (44%) | 1 (7%) | 18 (62%) |
| Ciclo alone | 5 (12%) | 0 | 5 (17%) |
| Other | 2 (5%) | 0 | 2 (7%) |
| Unknown | 2 (5%) | 1 (7%) | 1 (3%) |
| . | Total . | MAC . | RIC/NMA . |
|---|---|---|---|
| N | 43 | 14 | 29 |
| Age, y | 57 (20-72) | 36 (20-50) | 61 (32-72) |
| Sex (M/F) | 29/14 | 8/6 | 21/8 |
| F → M | 11 (26%) | 3 (21%) | 8 (28%) |
| Other | 32 (74%) | 11 (79%) | 21 (72%) |
| Time from diagnosis, d | 170 (107-1050) | 147.5 (110-520) | 193 (107-1050) |
| Disease status at HSCT | |||
| CR1 | 34 (79%) | 12 (86%) | 23 (79%) |
| CR2 | 5 (12%) | 1 (7%) | 4 (14%) |
| No CR | 2 (5%) | 1 (7%) | 0 |
| Unknown | 2 (5%) | 0 | 2 (7%) |
| Donor | |||
| Sibling | 19 (44%) | 8 (57%) | 11 (38%) |
| MUD | 10 (23%) | 1 (7%) | 9 (31%) |
| MMUD | 7 (16%) | 4 (29%) | 3 (10%) |
| Cord blood | 6 (14%) | 1 (7%) | 5 (17%) |
| Mismatch relative | 1 (2%) | 0 | 1 (3%) |
| Conditioning regimen | |||
| MAC | 14 (33%) | 14 (100%) | NA |
| Cy/TBI-based | 11 (26%) | 11 (79%) | NA |
| Cy/Bu | 3 (7%) | 3 (21%) | NA |
| RIC/NMA | 29 (67%) | NA | 29 (100%) |
| Flu/Bu/ALG | 10 (23%) | NA | 10 (34%) |
| Flu/2 Gy-TBI | 10 (23%) | NA | 10 (34%) |
| Sequential* | 5 (12%) | NA | 5 (17%) |
| Other† | 4 (9%) | NA | 4 (14%) |
| TBI-based | 23 (53%) | 11 (79%) | 12 (41%) |
| Cell source | |||
| Bone marrow | 7 (16%) | 5 (36%) | 2 (7%) |
| Peripheral blood | 30 (70%) | 8 (57%) | 22 (76%) |
| Cord blood | 6 (14%) | 1 (7%) | 5 (17%) |
| CMV status (D/R) | |||
| −/− | 18 (42%) | 6 (43%) | 12 (41%) |
| −/+ | 9 (21%) | 1 (7%) | 8 (28%) |
| +/− | 4 (9%) | 2 (14%) | 2 (7%) |
| +/+ | 12 (28%) | 5 (36%) | 7 (24%) |
| GVHD prophylaxis | |||
| Ciclo/MTX | 15 (35%) | 12 (86%) | 3 (10%) |
| Ciclo/MMF | 19 (44%) | 1 (7%) | 18 (62%) |
| Ciclo alone | 5 (12%) | 0 | 5 (17%) |
| Other | 2 (5%) | 0 | 2 (7%) |
| Unknown | 2 (5%) | 1 (7%) | 1 (3%) |
Age and time from diagnosis are shown as median (range). Other variables are shown as number (percentage).
ALG, antilymphocyte globulin; Bu, busulfan; Ciclo, ciclosporin; CR, complete remission; Cy, cyclophosphamide; D, donor; F, female; Flu, fludarabine; GVHD, graft-versus-host disease; Gy, Gray; M, male; MMF, mycophenolate mofetil; MMUD, mismatched unrelated donor; MTX, methotrexate; MUD, (10/10) matched unrelated donor; NA, not applicable; R, recipient; TBI, total-body irradiation.
Sequential conditioning regimen consisted of amsacrine/aracytine/Flu/Cy/ALG combined either with Bu in 4 patients or 2 Gy-TBI in 1.
Other conditioning regimen consisted of Flu/aracytine/2 Gy-TBI (1), Flu/Bu/ALG/Thiotepa (1), Cy/total lymphoid irradiation (1), and Flu/melphalan (1).